NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled